Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin
Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Liraglutide is a GLP1 agonist used in the treatment of Type 2 diabetes and is is asociated
with improved blood glucose control, weight loss and low rates of hypoglycemia when used
alone or in combination with metformin. Liraglutide has not been extensively tested in people
with type 2 diabetes who are taking relatively large doses of insulin (>50 U/day). Often
these patients are insulin resistant and despite using large doses of insulin are not able to
achieve glucose targets. The rationale for this study is to assess if the addition of
liraglutide in addition to usual care versus placebo can improve blood glucose levels in
people not achieving a target HbA1C of less than 7.0%.